Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval. Serious side effects reported with Merilog include hypoglycemia, severe allergic ...
Hosted on MSN1mon
Sanofi gets FDA approval for NovoLog insulin biosimilarThe FDA approved 3 mL single-patient-use prefilled pen and 10 mL multiple-dose vial versions of the drug. Merilog is the first rapid-acting insulin biosimilar to be approved by the agency.
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results